A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Key facts

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Principal Investigator

Chuanlin Wang, MD, MD

Peking University People's Hospital

Intervention

GR2001(biological)

Enrollment

582 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2025

Study locations (20)

• The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Peking University People Hospital, Beijing, Beijing Municipality, China
• Beijing Tiantan Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
• The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
• Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong, China
• Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
• Liuzhou People's Hospital, Liuchow, Guangxi, China
• Liuzhou Workers's Hospital, Liuchow, Guangxi, China
• The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
• The Central Hospital of Wuhan, Wuhan, Hubei, China
• Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
• Nanhua Hospital Affiliated to University of south China, Hengyang, Hunan, China
• The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tetanus

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE1NCT07149454
  Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
  Lanzhou Institute of Biological Products Co., Ltd
• RECRUITINGNCT07107932
  A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
  Zhuhai Trinomab Pharmaceutical Co., Ltd.

See all trials for Tetanus →